Comparative Pharmacology
Head-to-head clinical analysis: DEHYDRATED ALCOHOL versus SOTRADECOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEHYDRATED ALCOHOL versus SOTRADECOL.
DEHYDRATED ALCOHOL vs SOTRADECOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
Intravenous administration: 0.1-1 mL of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 mL, repeated up to 3 times per session depending on lesion size.
0.5 mL per injection site, multiple sites per session; maximum volume 10 mL per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
None Documented
None Documented
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/dL/hour in non-tolerant individuals.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Category C
Category C
Sclerosing agent
Sclerosing agent